Document Detail


The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
MedLine Citation:
PMID:  20655987     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hepatocyte growth factor (HGF) and its receptor MET are essential during embryonic development and throughout postnatal life. However, aberrant MET activation, due to overexpression, mutations, or autocrine ligand production, contributes to the development and progression of a variety of human cancers, often being associated with poor clinical outcome and drug resistance. B cell malignancies arise from B cells that are clonally expanded at different stages of differentiation. Despite major therapeutic advances, most mature B cell malignancies remain incurable and biologically-oriented therapeutic strategies are urgently needed. This review addresses the role of the HGF/MET pathway during B cell development and discusses how its aberrant activation contributes to the development of B cell lymphoproliferative disorders, with particular emphasis on multiple myeloma and diffuse large B cell lymphoma. These insights, combined with the recent development of clinical-grade agents targeting the MET pathway, provide the rationale to envision the HGF/MET pathway as a new promising target for the treatment of B cell malignancies.
Authors:
Karène Mahtouk; Esther P M Tjin; Marcel Spaargaren; Steven T Pals
Related Documents :
3709687 - A second growth state for schizosaccharomyces pombe.
14514237 - Effect of hydroxamic acid-based matrix metalloproteinase inhibitors on human gingival c...
18812567 - High-throughput analysis of hgf-stimulated cell scattering.
2824537 - Platelet-derived growth factor/sis in normal and neoplastic cell growth.
11273737 - Modulating effects of mucoregulating drugs on the attachment of haemophilus influenzae.
20395427 - Sex determination in mammalian germ cells: extrinsic versus intrinsic factors.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-07-22
Journal Detail:
Title:  Biochimica et biophysica acta     Volume:  1806     ISSN:  0006-3002     ISO Abbreviation:  Biochim. Biophys. Acta     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-29     Completed Date:  2011-02-08     Revised Date:  2012-06-04    
Medline Journal Info:
Nlm Unique ID:  0217513     Medline TA:  Biochim Biophys Acta     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  208-19     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Affiliation:
Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Differentiation
Hepatocyte Growth Factor / antagonists & inhibitors,  chemistry,  physiology*
Humans
Lymphoma, B-Cell / drug therapy,  etiology*
Multiple Myeloma / drug therapy,  etiology*
Proto-Oncogene Proteins c-met / antagonists & inhibitors,  chemistry,  physiology*
Receptors, Growth Factor / antagonists & inhibitors,  chemistry,  physiology*
Signal Transduction / physiology*
Chemical
Reg. No./Substance:
0/Receptors, Growth Factor; 67256-21-7/Hepatocyte Growth Factor; EC 2.7.10.1/MET protein, human; EC 2.7.10.1/Proto-Oncogene Proteins c-met

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel dienelactone hydrolase from the thermoacidophilic archaeon Sulfolobus solfataricus P1: Purif...
Next Document:  Acute and chronic exercise modulates the expression of MOR opioid receptors in the hippocampal forma...